382 results about "Gastric acid" patented technology

The invention discloses a vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions and a preparation method and application thereof, the vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions comprises three layers, namely a core layer, a middle layer and an outer layer from inside to outside in sequence; the core layer is formed by coating vitamin K2 with a zein-lac hydrophobic core, the middle layer is a pea protein-pectin electrostatic compound, and the outer layer is sodium alginate and chitosan double-network gel. The micro-capsule system provided by the invention can be tightly combined in a gastric acid environment after being orally taken, the release of active ingredients in the stomach is reduced, and then the micro-capsule system stays at intestinal mucosa for a long time and slowly releases contents, so that the functions of the micro-capsule system are slowly presented outside, the half-life period is prolonged, and the action effect is improved. Vitamin K2 directly or indirectly participates in and regulates various physiological processes related to health, and plays an important role in the aspects of maintaining bone health, preventing cardiovascular diseases, protecting nerves, improving metabolism and the like.

The invention discloses a hydrogel patch for gastric perforation repair and a preparation method thereof, and belongs to the technical field of biomedical materials. The preparation method comprises the following steps: dissolving acryloyl valine, acrylic acid, methylene bisacrylamide, a compound A and a photoinitiator in an alcohol solvent, and defoaming to obtain a precursor solution; and placing the precursor solution in a mold, carrying out ultraviolet-induced curing, soaking the obtained hydrogel in a hydrochloric acid solution, and replacing the alcohol solvent to obtain the hydrogel patch for gastric perforation repair. The hydrogel patch provided by the invention has the advantages of strong acid corrosion resistance, good biocompatibility, low swelling ratio, stable adhesion performance in a fluctuating pH environment and the like. The tough and stable adhesion performance ensures that the hydrogel can be permanently and reliably adhered to a gastric perforation part in a dynamic gastric acid environment, and a stable platform is provided for drug delivery, so that the surgical operation time is expected to be shortened, and wound healing is promoted.

The invention discloses a compound feed for raising plateau live pigs and a preparation method thereof, and relates to the technical field of feed processing. The compound feed for raising the plateau live pigs is prepared from manganese-selenium compound modified charcoal, soybean polysaccharide polylysine-based supported nanoparticles, aspergillus oryzae, soybean meal powder, corn flour, wheat bran, mountain flour, calcium hydrophosphate, table salt and multivitamins. Manganese-selenium composite modified charcoal, soybean polysaccharide polylysine-based supported nanoparticles and aspergillus oryzae are subjected to co-fermentation culture to form a uniform, stable, loose and porous three-dimensional network fermentation substrate composite system, so that the damage of gastric acid to components is reduced, the targeted release of intestinal tracts is realized, and the bioavailability is improved. The composite functional additive which is high in nutrition, easy to absorb, anti-oxidation, anti-anemia, anti-ultraviolet radiation and the like is obtained, and the adverse effects of low temperature, oxygen deficit and ultraviolet factors on animal growth and feed oxidative rancidity are effectively reduced.

The invention discloses a bacillus coagulans feed additive and a preparation method thereof, and relates to the technical field of feed additives, the bacillus coagulans feed additive comprises bacillus coagulans spores, the content of the spores is 1.0 * 10 < 8 >-1.0 * 10 < 11 > CFU / g; the protective agent system comprises the following components: maltodextrin or lactose, vegetable protein, polyhydric alcohol and an antioxidant; the invention discloses a microcapsule coating structure. A microcapsule is a two-layer composite coating of an inner layer alginate matrix and an outer layer polycation or polymer coating. According to the invention, bacillus coagulans spores which can still keep high survival rate under short-time high-temperature and low-pH conditions are obtained through screening and fermentation strategies of strains with high sporulation and heat and acid tolerance, the problem that common strains are easy to inactivate in granulation, extrusion and gastric acid environments is solved, the problem of product failure caused by insufficient tolerance of the strains is reduced, and the product quality is improved. And the original biological activity basis is improved, so that the protection effect of the subsequent formula and the coating can be played at a higher starting point, and the zoology effect of the final preparation is improved.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

The present application belongs to the technical field of biological medicine, and particularly relates to a chitosan-embedded probiotic gel microcapsule, a preparation method thereof and application of the microcapsule in preparation of an anti-Helicobacter pylori infection medicament. The superfine chitosan powder is used as a coating of the probiotic gel microcapsule, which is conducive to maintaining a high pH value in the microcapsule for a long time and providing a good living environment for the probiotic bacteria. Moreover, after the microcapsule enters the body, the peripheral chitosan powder first contacts the strong acid environment in the gastric juice, thereby providing a certain buffer barrier for the probiotic bacteria and the strong acid environment, so that the probiotic bacteria are prevented from being inactivated by the strong acid gastric acid. Meanwhile, the protonated chitosan shell plays a bridging role to make the microcapsule adsorbed on the gastric wall, thereby increasing the residence time of the microcapsule in the stomach, prolonging the time for the probiotic bacteria such as Bacillus natto to exert an ecological effect in the gastric juice, and finally achieving a good inhibitory effect on Helicobacter pylori.

The invention discloses nano-enzyme coating recombinant probiotics as well as a preparation method and application thereof, and belongs to the technical field of biotechnology and nano medicine. According to the invention, engineered Escherichia coli Nissle 1917 (ECN (DE3)) is taken as a host, and glutathione peroxidase (GPX) and glutathione reductase (GR) genes are over-expressed through a genetic engineering means, so that an efficient antioxidant enzyme system is constructed. And sequentially modifying chitosan and cerium dioxide nano-enzyme (CNP) on the surfaces of the thalli by using an electrostatic layer-by-layer self-assembly technology to form a protective coating. The nano-enzyme coating significantly improves the survival rate of the recombinant probiotics in severe environments such as simulated gastric acid (pH 2.5) and bile salt (0.3%), and enhances the ability of the recombinant probiotics to remove reactive oxygen species (ROS), including hydrogen peroxide, superoxide anions, hydroxyl free radicals and DPPH free radicals.

The invention relates to the technical field of functional microbial preparations, in particular to a biological preparation for relieving intestinal discomfort caused by alcohol and a preparation method and application thereof.The main technical scheme is that the biological preparation is prepared from, by weight, 5-20 parts of bacillus coagulans, 10-30 parts of pediococcus pentosaceus, 5-10 parts of lactobacillus rhamnosus and 0-20 parts of saccharomycetes. 0-5 parts of bifidobacterium longum and 0-5 parts of lactococcus lactis. By constructing an alcohol metabolism-intestinal protection dual-function synergistic system, specific florae such as bacillus coagulans, pediococcus pentosaceus and lactobacillus rhamnosus are scientifically compatible with functional components such as inulin and L-cysteine, alcohol is efficiently metabolized, and a carbon source is generated; the technical problems of low metabolic efficiency, weak intestinal protection and serious gastric acid inactivation of a traditional product are comprehensively solved.

The invention discloses a microsphere entrapped with probiotics and ginsenoside as well as a preparation method and application of the microsphere, and aims to realize efficient treatment of flora imbalance inflammatory bowel disease (IBD). The microspheres adopt a bi-component synergistic entrapment technology, can stably bear probiotics and ginsenoside, effectively avoid inactivation or degradation of the probiotics and ginsenoside in gastric acid and cholate environments, and ensure directional release and efficient utilization of the probiotics and ginsenoside in intestinal tracts. The microspheres not only provide a protection effect as a delivery carrier, but also construct a'microreactor 'system, and provide a suitable microenvironment for survival of probiotics and conversion of ginsenoside. Probiotics secrete a specific enzyme to promote prototype ginsenoside to be converted into rare ginsenoside with higher activity and stronger solubility while regulating intestinal flora balance and relieving intestinal inflammation, so that the bioavailability and efficacy of the rare ginsenoside are remarkably improved. According to the microsphere system, the technical bottlenecks of the existing treatment means in the aspects of activity maintenance, directional release and conversion utilization are broken through by realizing the synergistic effect of the probiotics and the ginsenoside, and a brand-new strategy and a technical platform are provided for treatment of flora imbalance related diseases such as IBD.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention relates to a gastric acid-resistant sustained-release intestinal bacteria capsule based on bionic mucous membrane-enzymolysis response and a preparation method thereof. The gastric acid-resistant sustained-release intestinal bacteria capsule comprises a core layer, an adhesive layer, an outer-layer composite film and a protective coating from inside to outside, the core layer consists of intestinal flora and a multifunctional freeze-drying protective agent; the adhesive layer is composed of trehalose, N-acetyl glucosamine and MUC2 recombinant protein; the outer-layer composite film is composed of a base material and a functional filler; the protective coating is composed of beewax and chitosan. The anti-gastric acid sustained-release intestinal bacteria capsule based on bionic mucosa-enzymolysis response provided by the invention has excellent gastric acid resistance, and the gastric acid resistance is remarkably improved; good slow release performance is achieved, and accurate slow release of enzymatic hydrolysis response can be achieved; the colonization efficiency of the intestinal bacteria can be effectively improved; the storage stability is good. The preparation method provided by the invention has the advantages of simplified steps, short time consumption, controllable core operation time and obviously shortened whole process, and is beneficial to keeping the activity of the flora.

The invention relates to the technical field of microcapsule preparation, and particularly discloses a microcapsule composition with a slow release function and a preparation method and application of the microcapsule composition. Soybean protein provided by the invention is subjected to three-stage hydrolysis to generate small molecule peptide and amino acid, and the small molecule peptide and amino acid can be interwoven with maltodextrin in a network structure; therefore, a compact and coherent composite wall material network structure is jointly constructed, erosion of gastric acid can be effectively resisted, and physical isolation protection is provided for probiotics. When the microcapsule enters an environment from neutral to alkalescent intestinal tracts, the pH value in the intestinal tracts is increased, and an original hydrogen bond network structure among molecules is damaged, so that an original compact gel network structure becomes loose and is greatly swelled; meanwhile, the hydrolyzed soybean protein can be further hydrolyzed under the action of intestinal trypsin and the like, the wall material structure of the microcapsule is gradually loosened, thalli are gradually released in the swelling-disintegration process, targeted slow release of the intestinal tract is achieved, and therefore the probiotic function of the microcapsule is achieved.

The invention provides a bovine colostrum probiotic compound preparation as well as a preparation method and application thereof. The compound preparation provided by the invention comprises the bovine colostrum powder subjected to activity protection and the compound probiotics, and the bovine colostrum powder subjected to activity protection is obtained by adopting a microcapsule double-layer embedding and freeze-drying technology, so that the gastric acid retention rate (2h) of immune globulin in the bovine colostrum powder is greater than or equal to 90%, and IgG contained in the bovine colostrum powder is ensured to be efficiently delivered to intestinal tracts to play an immune regulation role. Wherein the compound probiotics comprise four stages of functional echeles formed by more than or equal to 6 strains, and the four stages of functional echeles comprise colon colonization major flora, gastric acid-resistant pioneer flora, antibacterial peptide secretion auxiliary flora and inflammation regulation backup flora. Through cooperation of the components in the compound preparation, the compound preparation has excellent immune enhancement and metabolic regulation functions.

The invention discloses an easily absorbable organic calcium powder containing mineral elements and a preparation process thereof, and the raw materials comprise, by weight, 50-70 parts of an organic calcium source, 20-30 parts of a plant protein source, 5-10 parts of a polybasic amino acid chelate, 0.01-0.03 part of vitamin D3, 1-3 parts of trace mineral elements, 0.5-1.5 parts of compound protease, 0.1-0.3 part of a food-grade surfactant, and 100-150 parts of deionized water. The invention relates to the technical field of nutritional supplements. According to the mineral element-containing easy-to-absorb organic calcium powder and the preparation process, vegetable protein is converted into amino acid through biological enzymolysis, the amino acid and calcium carbonate are subjected to a chelation reaction to generate amino acid chelated calcium, and compared with traditional organic calcium, chelated calcium is more easily absorbed by human intestinal tracts; meanwhile, calcium, magnesium and phosphorus are synergistically matched, magnesium can activate vitamin D3, the vitamin D3 further promotes absorption of calcium, phosphorus and calcium form a reasonable proportion, deposition of calcium in bones is enhanced, and calcium ions can be absorbed in intestinal tracts without depending on gastric acid by adopting a bicyclic stable chelating structure.

Use of a bitter melon exosome and an oral medicament prepared therefrom. The bitter melon exosome obtained from the bitter melon juice can be used for preparing a pharmaceutical formulation embedding a protein, a polypeptide, a small molecule peptide, a nucleic acid, or a small molecule compound. The compositions of the oral medicament of the present invention comprise the bitter melon exosome and an active pharmaceutical ingredient encapsulated in the bitter melon exosome. The bitter melon exosome is suitable for preparing a drug that is easily damaged by the gastrointestinal tract and is mostly administered by means of an injection route into an oral agent, and the oral agent can produce a similar therapeutic effect to that of the injection administration route by oral administration, and is convenient to use. The extraction method for the bitter melon exosome is simple and has a low cost. Moreover, the bitter melon exosome has no immunogenicity, has relatively high biocompatibility and biosafety, and has relatively strong tolerance to gastric acid and digestive tract proteolytic enzymes, and intestinal barrier permeability.

The invention belongs to the technical field of biological medicine, and relates to an oral peptide drug delivery system based on a soybean trypsin inhibitor and core-shell hydrogel, the oral peptide drug delivery system comprises therapeutic polypeptide, KTI and a core-shell structure gel matrix, and the problems that an existing oral peptide delivery system is passively protected and drug burst release is remarkable are solved. A chitosan / sodium tripolyphosphate ionic cross-linked network forms an inner core, a sodium alginate / calcium ion'egg box 'structure cross-linked network forms a shell, and therapeutic polypeptides such as liraglutide and KTI are jointly embedded. Through the pH response characteristic and sequential release design of the core-shell structure, KTI is preferentially and rapidly released in the intestinal environment to inhibit local protease activity, then therapeutic polypeptide is slowly released, and active protection and synergistic interaction are achieved. The invention further provides a specific preparation method and parameters. The polypeptide has the advantages of stable structure in a gastric acid environment, targeted release in intestinal tracts, high encapsulation efficiency, capability of avoiding burst release and the like, and provides a new strategy for efficient delivery of oral polypeptide drugs.

A heterobicyclic derivative represented by chemical formula (I), according to the present invention, has a reversible proton pump inhibitory effect, and thus the heterobicyclic derivative and a pharmaceutical composition comprising same can be effectively used as a therapeutic agent for diseases associated with gastric acid secretion, particularly, as P-CAB.

The invention discloses a peptidomimetic compound as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The peptidomimetic compound is shown as a formula I in the specification. The compound can act on the nerve center, has anti-epilepsy and anti-depression effects, can also act on the gastrointestinal tract, inhibits gastric acid secretion or tumor cell growth, is a novel cholecystokinin type 2 receptor antagonist, and has a great application prospect.

The application belongs to the field of SOD preparation, and discloses a preparation method and device of SOD resistant to pepsin degradation, which comprises the following steps: S1 powder preparation: dissolving SOD fermentation pure liquid in a buffer solution with pH of 5.2-7.8, adding protective agent and tea yellow in sequence, stirring, filtering, and placing in a freeze dryer to prepare freeze-dried powder; S2 drying; S3 tabletting; S4, coating liquid preparation: dissolving wheat gliadin and soybean protein in a mixed solution prepared from water and ethanol with a volume ratio of 1:1, wherein the mass ratio of the wheat gliadin and the soybean protein is 0.5-1:1, adding glycerol, stirring for 20 min by using a magnetic stirrer, and ultrasonicating for 40 s; S5, coating: placing the tablets in a coating machine, setting air inlet volume, air inlet temperature, pan rotating speed, atomization rate, fan face pressure, and mortar flow, until the coating weight increases to 3%-10% in mass fraction and the coating thickness is 20-50 μm, and then drying and cooling. The prepared SOD is not easy to be photolyzed and can resist gastric acid degradation to ensure the complete activity of the SOD.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or Helicobacter pylori infection.

The application discloses a functional probiotic microencapsulated intestinal shield system and a preparation method and application thereof. A core layer comprises four probiotics, i.e., lactobacillus acidophilus La-14, animal bifidobacterium Bb-12, lactobacillus rhamnosus GG and lactobacillus reuteri DSM 17938, and the weight ratio is 3:4:2:1, and the total viable bacterial count is greater than or equal to 10^10 CFU / g. An inner layer is a targeted release control layer, which is composed of ethyl cellulose, polylactic acid, chitosan and lactose, can swell in a pH 5.5 to 6.5 environment and can dissolve in a pH 6.8 to 7.2 environment. A middle layer is a buffer protection layer, which is composed of calcium carbonate, disodium hydrogen phosphate and sodium alginate, and can maintain the internal pH of the microcapsule at 4.5 to 5.5 in a gastric acid environment. An outer layer is an intelligent response protection layer, which is composed of konjac glucomannan, xanthan gum and gum arabic, and can form a protective film in a gastric acid environment with a pH less than 3.0 within 5 minutes. Through the synergistic protection of the four-layer microcapsule structure, the probiotics can achieve a high survival rate in the gastric acid environment of cats, and can be accurately released at specific positions in the intestinal tract, which is helpful to improve the intestinal health of cats.

The invention discloses a probiotic strain Bifidobacterium animalis subsp. Lactiss S8 of a high-yield biological membrane, the preservation number is GDMCC NO.66518, the characteristics of the stable high-yield biological membrane are obtained through directional screening and adaptive evolution, and the yield of the biological membrane is three times higher than that of a positive control. The extracellular polymeric substance (EPS) of the strain can significantly enhance the tolerance of the strain to severe environments such as gastric acid, cholate and the like, and improve the intestinal colonization ability. Experiments prove that the strain remarkably reduces two liver function indexes, namely ALT and AST, in an animal model, and shows that the strain has a certain effect of improving liver injury.

The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder, and belongs to the technical field of compound amoxicillin, and the method comprises the following steps: (1) simulating a gastric acid environment, and respectively adding different compound amoxicillin powder samples to obtain different sample solutions; (2) simulating a small intestine environment for different sample solutions obtained in the step (1); and (3) sampling different sample solutions after the step (2), measuring the minimum inhibitory concentration, and comparing the effect of the compound amoxicillin powder sample to evaluate. The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder. The method is simple to operate and can quickly and accurately evaluate the effect of the compound amoxicillin powder.

A composition for use in a method of providing sustained energy release over time in a subject is described. The composition comprises or consists of microparticles comprising high glycaemic index (GI) carbohydrate contained within a gastric-resistant, ileal-sensitive, GLP-1 stimulative, non-porous carrier configured for release of the high GI carbohydrate in the ileum, wherein the composition is administered orally to the subject.

This invention relates to the crystal form of vonorazine pyroglutamate and its preparation method. The vonorazine pyroglutamate crystal form obtained by this invention not only has good solubility but also excellent storage stability; in vitro activity experiments show that crystal form I of this invention is effective against H+. + K + The inhibitory effect of ATPase is comparable to that of TAK-438; animal experiments show that the crystal form of the present invention, when administered intravenously, can significantly inhibit histamine-induced gastric acid secretion in rats, and can exert its pharmacological effect faster than that of TAK-438 administered duodenally.

The invention belongs to the technical field of medicines, and particularly relates to a bifunctional compound with anti-helicobacter pylori and acid inhibition activity, a preparation method of the bifunctional compound and application of the bifunctional compound in preparation of medicines for treating peptic ulcer and helicobacter pylori infection. According to the compound, a potassium ion competitive acid blocker vonoprazan is used as an acid inhibition unit, and rifobetine is used as an anti-helicobacter pylori unit; the two compounds are respectively subjected to covalent modification through linking groups Linker 1 and Linker 2, and then are connected by virtue of a triazole ring to form a series of bifunctional compounds shown as a general formula (I). The compound can simultaneously and synergistically act on two key targets of gastric acid secretion and helicobacter pylori, so that not only is the treatment effect remarkably enhanced, but also better safety is shown due to the fact that the same curative effect can be achieved at a lower dosage.

The invention discloses a composite capsule with synergistic stomach-nourishing and anti-inflammatory effects and a preparation method thereof, and relates to the technical field of functional foods, health care products and medicines. The lactic acid bacteria, the egg yolk globulin and the dandelion extract are used as main raw materials to prepare the composite capsule, the ratio of the raw materials is optimized, the three raw materials in the composite capsule generate a synergistic effect, triterpenoid components in the dandelion extract can inhibit helicobacter pylori, and the triterpenoid components, the lactic acid bacteria and the egg yolk globulin jointly repair gastrointestinal mucosa, so that the gastric mucosa is inhibited, and the gastric mucosa is prevented from being damaged. Gastrointestinal health is synergistically regulated, and resistance is enhanced; meanwhile, the dandelion extract and the egg yolk globulin serve as protective carriers, the survival rate of the lactic acid bacteria in gastric acid is increased, and experimental data shows that the survival rate is increased to 81% from 30%; compared with a single formula, the compound capsule can increase the survival rate of lactic acid bacteria and increase the bioavailability of the dandelion extract by enhancing the immune effect of egg yolk globulin.

The application provides a microcapsule of triterpenoid compounds of Radix Morindae Officinalis and a preparation method thereof. The preparation method is as follows: taking Radix Morindae Officinalis powder as raw material, first extracting with ethanol under ultrasonic, then extracting with ethyl acetate to obtain triterpenoid compounds of Radix Morindae Officinalis; mixing malt dextrin and gum arabic, dissolving in water to obtain a wall material solution; adding the triterpenoid compounds of Radix Morindae Officinalis into the wall material solution, then adding glycerol monostearate, stirring to obtain an emulsion; spray drying the emulsion to obtain the microcapsule of triterpenoid compounds of Radix Morindae Officinalis. The application also provides application of the microcapsule in preparation of antibacterial drugs or antioxidant active drugs. The extracted triterpenoid compounds of Radix Morindae Officinalis and the microcapsule based on the compounds have good antibacterial and antioxidant activities; through the microencapsulation method, the microcapsule has good water solubility, can avoid being attacked by gastric acid, has the effect of being released fully in the small intestine, and has the advantages of high sustained-release stability and high effective component utilization rate.

The invention discloses a lactoferrin gel carrier, a preparation method thereof and application of the lactoferrin gel carrier in an oral delivery system. The preparation method comprises the following steps: mixing a lactoferrin solution with transglutaminase, and reacting under mild conditions to form a gel network. According to the method, gel which is compact in structure and high in stability is formed through enzyme catalytic crosslinking, the mechanical strength and embedding capacity of the gel are remarkably enhanced, and the method is suitable for embedding multiple active ingredients (such as probiotics, polyphenol and vitamins) sensitive to heat, oxygen or shear force. The obtained gel carrier can effectively isolate oxygen, moisture and adverse processing environments, and the stability of embedded components in processing, storage and transportation is remarkably improved. The carrier can be slowly released in a gastrointestinal tract environment, and active ingredients are prevented from being degraded too early in gastric acid, so that the intestinal absorption rate and the bioavailability of the carrier are improved. The materials used in the invention are natural proteins, are safe and non-toxic, and accord with food and health care product application standards.